Cargando…
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
The PI3K/AKT/mTOR pathway has long been known to play a major role in the growth and survival of cancer cells. Breast tumors often harbor PIK3CA gene alterations, which therefore constitute a rational drug target. However, it has taken many years to demonstrate clinically-relevant efficacy of PI3K i...
Autores principales: | Chang, Dwan-Ying, Ma, Wei-Li, Lu, Yen-Shen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943556/ https://www.ncbi.nlm.nih.gov/pubmed/33707948 http://dx.doi.org/10.2147/TCRM.S251668 |
Ejemplares similares
-
Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020) -
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020) -
Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
por: Yeom, Jiah, et al.
Publicado: (2023) -
Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib
por: Morin, Gabriel, et al.
Publicado: (2022) -
In vitro anticancer effects of alpelisib against PIK3CA-mutated canine hemangiosarcoma cell lines
por: Maeda, Marika, et al.
Publicado: (2022)